The impact of ethnicity and cardiovascular risk on the pharmacologic management of osteoarthritis: a US perspective

References

• Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58:26–35.
   PubMed Web of Science ®Google Scholar
• Grotle M, Hagen KB, Natvig B, Dahl F, Kvien TK. Prevalence and burden of osteoarthritis: results from a population survey in Norway. J Rheumatol 2008;35:677–84.
   PubMed Web of Science ®Google Scholar
• Salaffi F, Carotti M, Stancati A, Grassi W. Health-related quality of life in older adults with symptomatic hip and knee osteoarthritis: a comparison with matched healthy controls. Aging Clin Exp Res 2005;17:255–63.
   PubMed Web of Science ®Google Scholar
• Kotlarz H, Gunnarsson CL, Fang H, Rizzo JA. Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data. Arthritis Rheum 2009;60:3546–53.
   PubMed Web of Science ®Google Scholar
• Kotlarz H, Gunnarsson CL, Fang H, Rizzo JA. Osteoarthritis and absenteeism costs: evidence from US National Survey Data. J Occup Environ Med 2010;52:263–8.
   PubMed Web of Science ®Google Scholar
• White AG, Birnbaum HG, Janagap C, Buteau S, Schein J. Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States. J Occup Environ Med 2008;50:998–1005.
   PubMed Web of Science ®Google Scholar
• Lanas A, Garcia-Tell G, Armada B, Oteo-Alvaro A. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med 2011;9:38.
   PubMed Web of Science ®Google Scholar
• Richette P, Hilliquin P, Bertin P, Carni P, Berger V, Marty M. Comparison of general practitioners and rheumatologists’ prescription patterns for patients with knee osteoarthritis. BMC Musculoskelet Disord 2011;12:72.
   PubMed Web of Science ®Google Scholar
• Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115:1634–42.
   PubMed Web of Science ®Google Scholar
• Wilcox CM, Cryer B, Triadafilopoulos G. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. J Rheumatol 2005;32:2218–24.
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092–102.
   PubMed Web of Science ®Google Scholar
• Fosbol EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010;3:395–405.
   PubMed Web of Science ®Google Scholar
• Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006;113:2906–13.
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071–80.
   PubMed Web of Science ®Google Scholar
• Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011;123:2226–35.
   PubMed Web of Science ®Google Scholar
• Roth SH, Anderson S. The NSAID dilemma: managing osteoarthritis in high-risk patients. Phys Sportsmed 2011;39:62–74.
   PubMed Web of Science ®Google Scholar
• Sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009;374:1967–74.
   PubMed Web of Science ®Google Scholar
• Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 2009;8:669–81.
   PubMed Web of Science ®Google Scholar
• Evans JM, McGregor E, McMahon AD, et al. Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. QJM 1995;88:551–7.
   PubMed Web of Science ®Google Scholar
• Barkin RL, Beckerman M, Blum SL, Clark FM, Koh EK, Wu DS. Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging 2010;27:775–89.
   PubMed Web of Science ®Google Scholar
• Juhlin T, Bjorkman S, Gunnarsson B, Fyge A, Roth B, Hoglund P. Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors. Eur J Heart Fail 2004;6:909–16.
   PubMed Web of Science ®Google Scholar
• Juhlin T, Bjorkman S, Hoglund P. Cyclooxygenase inhibition causes marked impairment of renal function in elderly subjects treated with diuretics and ACE-inhibitors. Eur J Heart Fail 2005;7:1049–56.
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009;57:1331–46.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2011;123:2434–506.
   PubMed Web of Science ®Google Scholar
• Johnson J, Weinryb J. Safe pharmacologic treatment strategies for osteoarthritis pain in African Americans with hypertension, and renal and cardiac disease. J Natl Med Assoc 2006;98:1126–35.
   PubMedGoogle Scholar
• Booske BC, Robert SA, Rohan AM. Awareness of racial and socioeconomic health disparities in the United States: the national opinion survey on health and health disparities, 2008-2009. Prev Chronic Dis 2011;8:A73.
   PubMed Web of Science ®Google Scholar
• Braveman PA, Cubbin C, Egerter S, Williams DR, Pamuk E. Socioeconomic disparities in health in the United States: what the patterns tell us. Am J Public Health 2010;100:S186–96.
   PubMed Web of Science ®Google Scholar
• Palmer ND, McDonough CW, Hicks PJ, et al. A genome-wide association search for type 2 diabetes genes in African Americans. PLoS One 2012;7:e29202.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. CDC health disparities and inequalities report – United States, 2011. MMWR Morb Mortal Wkly Rep 2011;60(Suppl):1–113.
   Google Scholar
• Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 2012;125:e2–e220.
   PubMed Web of Science ®Google Scholar
• Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med 2012;366:321–9.
   PubMed Web of Science ®Google Scholar
• Borrell LN, Menendez BS, Joseph SP. Racial/ethnic disparities on self-reported hypertension in New York City: examining disparities among Hispanic subgroups. Ethn Dis 2011;21:429–36.
   PubMedGoogle Scholar
• Ventura H, Pina IL, Lavie CJ. Hypertension and antihypertensive therapy in Hispanics and Mexican Americans living in the United States. Postgrad Med 2011;123:46–57.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Hypertension related mortality among Hispanic populations-United States 1995-2002. MMWR Morb Mortal Wkly Rep 2006;55:177–80.
   PubMedGoogle Scholar
• Kirby JB, Liang L, Chen HJ, Wang Y. Race, place, and obesity: the complex relationships among community racial/ethnic composition, individual race/ethnicity, and obesity in the United States. Am J Public Health 2012;102:1572–8.
   PubMed Web of Science ®Google Scholar
• Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006;29:1263–8.
   PubMed Web of Science ®Google Scholar
• Ma Y, Hebert JR, Manson JE, et al. Determinants of racial/ethnic disparities in incidence of diabetes in postmenopausal women in the U.S.: the Women’s Health Initiative 1993-2009. Diabetes Care 2012;35:2226–34.
   PubMed Web of Science ®Google Scholar
• Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes 2010;2:180–93.
   PubMed Web of Science ®Google Scholar
• Ramos RG, Olden K. The prevalence of metabolic syndrome among US women of childbearing age. Am J Public Health 2008;98:1122–7.
   PubMed Web of Science ®Google Scholar
• Razzouk L, Muntner P. Ethnic, gender, and age-related differences in patients with the metabolic syndrome. Curr Hypertens Rep 2009;11:127–32.
   PubMed Web of Science ®Google Scholar
• Walker SE, Gurka MJ, Oliver MN, Johns DW, DeBoer MD. Racial/ethnic discrepancies in the metabolic syndrome begin in childhood and persist after adjustment for environmental factors. Nutr Metab Cardiovasc Dis 2012;22:141–8.
   PubMed Web of Science ®Google Scholar
• Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005;28:1769–78.
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta 2007;1770:489–94.
   PubMed Web of Science ®Google Scholar
• Martinez C, Blanco G, Ladero JM, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol 2004;141:205–8.
   PubMed Web of Science ®Google Scholar
• Dickmann LJ, Rettie AE, Kneller MB, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001;60:382–7.
   PubMed Web of Science ®Google Scholar
• Kramer MA, Rettie AE, Rieder MJ, Cabacungan ET, Hines RN. Novel CYP2C9 promoter variants and assessment of their impact on gene expression. Mol Pharmacol 2008;73:1751–60.
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder JS. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol 2001;79:841–7.
   PubMed Web of Science ®Google Scholar
• Gaikwad T, Ghosh K, Shetty S. VKORC1 and CYP2C9 genotype distribution in Asian countries. Thromb Res 2014;134:537–44.
   PubMedGoogle Scholar
• Le TK, Montejano LB, Cao Z, Zhao Y, Ang D. Health care costs in US patients with and without a diagnosis of osteoarthritis. J Pain Res 2012;5:23–30.
   PubMedGoogle Scholar
• Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64:465–74.
   PubMed Web of Science ®Google Scholar
• Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145–55.
   PubMed Web of Science ®Google Scholar
• Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006:CD004257.
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: prescription acetaminophen products to be limited to 325 mg per dosage unit; boxed warning will highlight potential for severe liver failure. Available from http://www.fda.gov/drugs/drugsafety/ucm239821.htm. Accessed 21 March 2014.
   Google Scholar
• Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am J Gastroenterol 2007;102:2459–63.
   PubMed Web of Science ®Google Scholar
• Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005;42:1364–72.
   PubMed Web of Science ®Google Scholar
• Norco™ (hydrocodone bitartrate and acetaminophen tablets). Full Prescribing Information [package insert]. Parsippany, NJ: Actavis Pharma, Inc; 2014.
   Google Scholar
• Xartemis™ XR (oxycodone hydrochloride and acetaminophen extended-release tablets). Full Prescribing Information [package insert]. Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc; 2014.
   Google Scholar
• Brok J, Buckley N, Gluud C. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev 2006:CD003328.
   PubMedGoogle Scholar
• Raffa RB, Buschmann H, Christoph T, et al. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother 2012;13:1437–49.
   PubMed Web of Science ®Google Scholar
• Ultram® (tramadol hydrochloride tablets). Full Prescribing Information [package insert]. Raritan, NJ: Ortho-McNeil; 2004.
   Google Scholar
• Peacock LE, Wright F. Serotonin syndrome secondary to tramadol and citalopram. Age Ageing 2011;40:528.
   PubMedGoogle Scholar
• Mahlberg R, Kunz D, Sasse J, Kirchheiner J. Serotonin syndrome with tramadol and citalopram. Am J Psychiatry 2004;161:1129.
   PubMed Web of Science ®Google Scholar
• Takeshita J, Litzinger MH. Serotonin syndrome associated with tramadol. Prim Care Companion J Clin Psychiatry 2009;11:273.
   PubMedGoogle Scholar
• Vizcaychipi MP, Walker S, Palazzo M. Serotonin syndrome triggered by tramadol. Br J Anaesth 2007;99:919.
   PubMed Web of Science ®Google Scholar
• Ultram® ER (tramadol hydrochloride). Full Prescribing Information [package insert]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc; 2009.
   Google Scholar
• Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113–30.
   PubMed Web of Science ®Google Scholar
• Leppert W. CYP2D6 in the metabolism of opioids for mild to moderate pain. Pharmacology 2011;87:274–85.
   PubMed Web of Science ®Google Scholar
• Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH, Brosen K. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 2005;77:312–23.
   PubMed Web of Science ®Google Scholar
• de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006;47:75–85.
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 2002;72:76–89.
   PubMed Web of Science ®Google Scholar
• Deal CL, Schnitzer TJ, Lipstein E, et al. Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther 1991;13:383–95.
   PubMed Web of Science ®Google Scholar
• McCarthy GM, McCarty DJ. Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands. J Rheumatol 1992;19:604–7.
   PubMed Web of Science ®Google Scholar
• Qutenza® (capsaicin 8% patch). Full Prescribing Information [package insert]. Ardsley, NY: Acorda Therapeutics, Inc; 2009.
   Google Scholar
• Huang TL, Chang CC, Lee CH, Chen SC, Lai CH, Tsai CL. Intraarticular injections of sodium hyaluronate (Hyalgan®) in osteoarthritis of the knee. A randomized, controlled, double-blind, multicenter trial in the Asian population. BMC Musculoskelet Disord 2011;12:221.
   PubMedGoogle Scholar
• Raynauld JP, Buckland-Wright C, Ward R, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2003;48:370–7.
   PubMed Web of Science ®Google Scholar
• Richmond J, Hunter D, Irrgang J, et al. Treatment of osteoarthritis of the knee (nonarthroplasty). J Am Acad Orthop Surg 2009;17:591–600.
   PubMed Web of Science ®Google Scholar
• Voltaren® Gel 1% (diclofenac sodium topical gel). Full Prescribing Information [package insert]. Parsippany, NJ: Novartis Consumer Health, Inc; 2009.
   Google Scholar
• PENNSAID® (diclofenac sodium topical solution). Full Prescribing Information [package insert]. Varennes, QC, Canada: Nuvo Manufacturing; 2010.
   Google Scholar
• Altman RD, Dreiser RL, Fisher CL, Chase WF, Dreher DS, Zacher J. Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009;36:1991–9.
   PubMed Web of Science ®Google Scholar
• Barthel HR, Haselwood D, Longley S, Gold MS, Altman RD. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. Semin Arthritis Rheum 2009;39:203–12.
   PubMed Web of Science ®Google Scholar
• Niethard FU, Gold MS, Solomon GS, et al. Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J Rheumatol 2005;32:2384–92.
   PubMed Web of Science ®Google Scholar
• Simon LS, Grierson LM, Naseer Z, Bookman AA, Zev Shainhouse J. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009;143:238–45.
   PubMed Web of Science ®Google Scholar
• Towheed TE. Pennsaid therapy for osteoarthritis of the knee: a systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2006;33:567–73.
   PubMed Web of Science ®Google Scholar
• Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004;31:2002–12.
   PubMed Web of Science ®Google Scholar
• Kienzler JL, Gold M, Nolleveaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol New Drugs 2010;50:50–61.
   Google Scholar
• Roth SH, Fuller P. Diclofenac sodium topical solution 1.5% w/w with dimethyl sulfoxide compared with placebo for the treatment of osteoarthritis: pooled safety results. Postgrad Med 2011;123:180–8.
   PubMed Web of Science ®Google Scholar
• Baraf HS, Gold MS, Petruschke RA, Wieman MS. Tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities. Am J Geriatr Pharmacother 2012;10:47–60.
   PubMed Web of Science ®Google Scholar
• Nelson AE, Allen KD, Golightly YM, Goode AP, Jordan JM. A systematic review of recommendations and guidelines for the management of osteoarthritis: the Chronic Osteoarthritis Management Initiative of the U.S. Bone and Joint Initiative. Semin Arthritis Rheum 2014;43:701–12.
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic Conditions. Osteoarthritis: national clinical guideline for care and management in adults. London, UK: Royal College of Physicians; 2008.
   Google Scholar